![Protagonist Therapeutics - VERIFY Study for PV 1 Protagonist Therapeutics logo](https://i0.wp.com/www.pvreporter.com/wp-content/uploads/2023/04/62715702596ddf36a6c14462_Protagonist_Logo_FullColor-1.jpg?resize=300%2C72&ssl=1)
Protagonist Therapeutics is the sponsor.
Rusfertide, also called PTG-300, is an investigational medication. Study participation will help evaluate how safe and effective rusfertide is in keeping the hematocrit levels within the recommended range to reduce the need for phlebotomies.
Summary:
VERIFY (NCT05210790) is a Phase 3 clinical study in approximately 250 subjects previously diagnosed with polycythemia vera (PV) who require phlebotomy on a routine basis.
There is a 32-week period during which rusfertide or placebo will be added-on to each subject’s ongoing therapy for polycythemia vera which may include phlebotomy only or phlebotomy plus stable doses of either of hydroxyurea, interferon and/or ruxolitinib.
All subjects who successfully complete the double blind 32-week portion of the study will receive rusfertide for 124 weeks. Approximately 6 and 12 months after their last dose of rusfertide, subjects will have a post-study contact (e.g. by phone) for safety.
Click here to learn more about the VERIFY study.
Learn More